Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

KB803

Gene therapy · Gene replacement · developed by Krystal Biotech

Phase 3 Most advanced trial
KRYS Developer
1 Registered trials

What is KB803?

KB803 is an ophthalmic suspension of a replication-defective, non-integrating herpes simplex virus type 1 vector that expresses the human collagen VII protein. It is being studied in dystrophic epidermolysis bullosa.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy
Mechanism
Gene replacement
Therapy area
Dermatology
Developer
Krystal Biotech, Inc. (KRYS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07016750 Phase 3 Dystrophic Epidermolysis Bullosa Recruiting KRYS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

DEB - Dystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis BullosaDystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa

More from Krystal Biotech

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KRYS page.

Follow KRYS, the company behind KB803

See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KRYS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.